Gingipain, one of the byproducts of P. gingivalis, is a novel therapeutic target for AD treatment, which is associated with AD-related pathologies, such as Aβ and tau pathology, neuroinflammation, and neurodegeneration (Table 3). The gene discussed is MAPT; the disease is Alzheimer disease.